



EBMT 2020 GENERAL ASSEMBLY MEETING; 2019 ACTIVITY REPORTS:

**President's Report
Treasurer's Report
Secretary's Report**

Tuesday 1st September, 2020 - 17h00-17h30 CET



President Annual Activity Report for 2019

Nicolaus Kröger, EBMT President



EBMT

European Society
for Blood and Marrow
Transplantation

Achievements in 2019 at a glance

SCIENCE

- **> 250** ongoing projects
- **138** publications in peer-reviewed journals
- **100** oral presentations at international meetings
- **17,767** allografts and **23,179** autografts reported to the Registry
- **337 CAR-T cells** treated patients registered in the Registry
- Collaboration with Novartis
- **701** centres reported **47,468** transplants in **42,901** patients from **50** countries to the Transplant Activity Survey 2018

EDUCATION

- **EBMT 45th Annual Meeting** in Frankfurt with **5,640** delegates from **94** countries
- **EBMT-EHA 1st European CAR T Cell Meeting** in Paris with 680 attendees
- **14 EBMT educational events**
- New EBMT **e-learning platform and webinars**

PATIENT CARE

JACIE

- **101** received applications; 43 applications included IEC in the scope of the accreditation process
- **71** performed inspections
- **78** awarded accreditations
- Kicked-off process to prepare the **8th Edition** of the FACT-JACIE standards

NURSES GROUP

- Educational meetings
- Medical Working Party Nurses
- Collaborative research projects




SCIENCE




The EBMT Registry

Allografts



Autografts




•By the end of 2019, the entire Registry included at least 709,000 transplant registrations in total.

•17,767 allografts and 23,179 autografts were registered in 2019.

New registrations for cell therapy

Number of CAR-T cell treated patients registered in the EBMT Registry



The Registry has actively encouraged centres to report on all cases involved in the treatment of patients using a CAR-T product whether commercial or investigational.

This graph (left) illustrates the steady growth of new reported cases into the EBMT Registry during 2019 and the reflected number of centres.

All centres should continue to complete the current Cellular Therapy Form outlined in ProMISe on a timely basis to create an accurate patient representation.

New registrations for cell therapy

Countries reporting CAR-T cell treated patients
to the EBMT Registry

■ Reporting countries



Source: EBMT Registry, December 2019

The 2nd graph (left) represents a geographical approach in blue of all our reporting countries who are continually processing data into the EBMT Registry.

We look forward to welcoming more countries in 2020 as the number of CAR-T products on the market steadily increases.

EMA'S QUALIFICATION OPINION ON CELLULAR THERAPY MODULE OF EBMT REGISTRY

28th February 2019: EBMT Registry qualified as a suitable platform for the collection of data for post-authorisation safety study (PASS).



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

GOVERNANCE STRUCTURE CAR T COMMUNITY

In the context of the qualification opinion on the cellular therapy module of the EBMT registry and the growing clinical use of CAR-T cell and IEC therapies, the EBMT has set up a governance structure for the CAR-T Community (approved by the EBMT Board during the June 2019 Board Meeting in Hamburg).

The EBMT Legal and Regulatory Affairs Committee and the cellular Therapy and Immunobiology Working Party **engaged with different key stakeholders** such as national transplantation groups; clinical CAR-T centers; disease-oriented scientific societies; pharmaceutical companies; patient advocates; health technology assessment bodies; regulators - to present and discuss this structure.

The last **stakeholder meeting** took place during the 2nd European CAR T Cell Meeting to further discuss individual roles in the different work packages.

CELLULAR THERAPY MED-A FORM

The EBMT is in the process of finalising the Cellular Therapy Med-A Form which plans to be a **robust stand-alone document** reflecting on current standard of treatment across our Hospital community.

This important data collection form is to be the basis of all **PASS CAR-T Studies** and will eventually be implemented into our new MACRO Electronic Data Capture system replacing ProMISe.

Any patient data that has been registered using the current Cellular Therapy Med-A Form in ProMISe will be **migrated into MACRO** during our ongoing data migration process which is currently taking place at the London Registry Office as of Q4 2019.

As competent authorities require a 15-year follow-up of recipients the staff at all our centres including data managers and clinical departments will be instrumental in **collating all the necessary patient data** both at the time of treatment and subsequent follow-up visits.

Registry upgrade


Substantial work has continued on this project during 2019 and in Q4 the production environment was made available allowing the **data transfer from ProMiSe to MACRO** to begin. The full system validation is due to take place in 2020.

Since February 2019 the Registry has rolled out a **data entry training program** to EBMT staff and data managers in the National Registries and Centres.

Almost all affiliated national societies have been providing training to centres in their region and we are very grateful for their collaboration.

Around 600 users have been trained in MACRO basics and data entry during 2019:

- **EBMT registry:**
London, UK
- **EBMT Annual Meeting:**
Frankfurt, Germany
- **National society:**
Turkey
Spain
Belgium
UK
France
Czech Republic
Germany
Italy
Switzerland
The Netherlands
- **Medical University of Warsaw:**
Warsaw, Poland
- **Evangelismos Hospital:**
Athens, Greece
- **Karolinska Institute:**
Stockholm, Sweden



Registry resource

In 2019 the Registry has transitioned from the previous Head **Carmen Ruiz de Elvira** to **Debra Gordon** who joined EBMT Registry in November 2018. EBMT would like to thank Carmen for her exceptional contribution, dedication and commitment that she has shown to the organisation over the past 20 years and wishes her well in her future endeavours.

EBMT welcomes Debra as Head of Registry.

The Registry has also proceeded to **hire a new data manager** experienced in MACRO alongside the expansion of our IT department which now has greater technical expertise much needed for the challenges of MACRO and delivery of our upcoming Registry IT Projects.



Carmen Ruiz de Elvira



Debra Gordon

Collaboration with Novartis

Beginning of 2020, the EBMT announced a new collaboration with Novartis Pharmaceuticals to study the long-term outcomes of patients treated with CAR T therapies.

Under the terms of the collaboration, EBMT will collect treatment and long-term safety and efficacy data from patients treated with Kymriah® (tisagenlecleucel) in both approved indications in the EBMT registry for cellular therapy in the European regions.

Transplant Activity Survey

HEMATOPOIETIC CELL TRANSPLANTATION

In 2018, 701 centers reported 47,468 transplants in 42,901 patients (first transplant) from 50 countries to the annual activity survey.

CELLULAR THERAPIES

In the 2018, 1,325 patients in 28 countries received hematopoietic cellular therapies (excluding donor lymphocyte infusions).



The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus

Jakob R. Passweg¹ · Helen Baldomero¹ · Christian Chabannon² · Grzegorz W. Basak³ · Selim Corbacioglu⁴ · Rafael Duarte⁵ · Harry Dolstra⁶ · Arjan C. Lankester⁷ · Mohamad Mohty⁸ · Silvia Montoto⁹ · Régis Peffault de Latour¹⁰ · John A. Snowden¹¹ · Jan Styczynski¹² · Ibrahim Yakoub-Agha¹³ · Nicolaus Kröger¹⁴ · for the European Society for Blood and Marrow Transplantation (EBMT)

Received: 23 December 2019 / Revised: 23 January 2020 / Accepted: 3 February 2020
© The Author(s) 2020. This article is published with open access

Abstract

Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year's analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.

Figure 1b:

ABSOLUTE NUMBERS OF PATIENTS RECEIVING OTHER NON CAR-T CELLULAR THERAPIES





Figure 1a:

ABSOLUTE NUMBERS OF PATIENTS RECEIVING CAR-T CELLULAR THERAPIES





EDUCATION





45th Annual Meeting
of the European Society for
Blood and Marrow Transplantation

24th–27th March 2019 · Frankfurt, Germany



More than 5,640
participants from 94
countries

1,068 submitted
abstracts




High educational productivity (1/2)

EDUCATIONAL EVENTS

14 cutting-edge educational events and courses in total organised by the Working Parties; Nurses Group and JACIE and attended by more than 2,100 participants in total.

- **1st European CAR T Cell Meeting** jointly organized by EBMT and EHA (14-16 Feb. 2019 in Paris – 680 attendees)
- **1st EBMT GVHD summit** (16-18 May 2019 in Warsaw – 234 attendees)
- **4th International Transplant Course** (6-8 September 2019 in Barcelona – 293 attendees)



High educational productivity (2/2)

E-LEARNING PLATFORM

The process for developing an e-learning platform to further educate the EBMT community has started in 2018 and it will be launched during the EBMT 2020 Annual Meeting in Madrid.

The e-learning materials include:

Nurses e-course
Educational webinars
CAR-T cell e-course
JACIE Inspector course



EBMT EXAM

The first edition of the EBMT Exam will be held on Sunday 30 August 2020 during the EBMT Annual Meeting.

The Exam has the aim to provide a personal qualification for physicians to assess their knowledge on the clinical aspects of Hematopoietic Stem Cell Transplantation and Cellular Therapies.

EBMT HANDBOOK

Release of the new EBMT Handbook in January 2019. The project started in 2017. The Handbook is composed of 93 chapters written by 175 leading experts in the field.





PATIENT CARE



EBMT Nurses Group (1/2)

PAEDIATRIC TRAINING DAYS

The Paediatricians and Paediatric Nurses held a training course in Regensburg on sickle cell disease on 16th and 17th May and this was a great success with nurses across Europe attending.

NURSES INTERNATIONAL STUDY DAY AND NURSES RESEARCH

2019 saw the 11th Nurses International Study Day and the 3rd Nurses Research Study hosted in Amsterdam. There was a wide spread of topics, with talks on chronic GvHD, endocrine dysfunction and care of the young adult, and thought-provoking programme.

JOINT EBMT EHA COLLABORATION

The joint EBMT EHA CAR-T Cell Meeting in Paris in January had a nurse's program which was well received and evaluated.

INTERNATIONAL TRAINING DAY

This is the first time that the Nurses Group has been invited along to the EBMT International Transplant Course. A well attended meeting held in Barcelona each October. The NG had a whole day and used it wisely to give presentations based on the JACIE competencies.

EBMT Nurses Group (2/2)

MEDICAL WORKING PARTY NURSES

This role is now firmly established as a valuable resource in each of the medical working parties. The goal to develop collaborative nursing/medical projects for patient benefit continues to develop at pace. The roles have begun to adapt to the needs of the WP with many nurses taking more responsibility for education.

GLOBAL EDUCATIONAL COMMITTEE

On the 1st and 2nd August the GEC visited Brasilia attending the LABMT annual meeting and giving 2 days of presentations. The GEC also visited Paraguay 2-3rd September and Argentina 30th October to 1st November and participated in the programs of education.

NURSING RESEARCH COMMITTEE

Publication in *Bone Marrow Transplantation* Polemeni et al.: "Haematopoietic cell transplant nurse coordinators' perceptions of related donor care: a European survey from the EBMT Nurses Group."


There are several projects currently recruiting or about to be launched by the EBMT nurses research group.




Highlights of the JACIE's activities



101 APPLICATIONS RECEIVED



71 INSPECTIONS PERFORMED




43 applications received in 2019 included Immune Effector Cells in the scope of the accreditation processes.

JACIE Accreditations

The full list of institutions awarded accreditation in 2019 is available at

78 ACCREDITATION AWARDS



Educational events and Standards



EDUCATIONAL EVENTS

Two JACIE training courses were held during 2019, both in Barcelona with 38 participants in total from 17 countries while 6 other meetings and events were dedicated to or included accreditation. Furthermore, in September, a joint JACIE-FACT workshop was held at the WBMT/WHO meeting in Asunción, Paraguay.

8TH EDITION OF FACT-JACIE STANDARDS

The process to prepare the 8th edition of the FACT-JACIE Standards kicked-off in mid-2019. The sub-committees commenced their review during the last months of 2019 and will complete their work in early 2020. The first draft will be opened for public consultation in April 2020 during 3 months.

Other achievements

Restructuring the organigram

In 2019 we restructured the managerial infrastructure of the EBMT and organized it in **six departments**: (1) Science, (2) Registry, (3) Educational, (4) JACIE, (5) Support and (6) Business. Each department is led by a department head that together with the Executive Director form the EBMT management team.

Furthermore, we recruited a **Medical Officer** (Isabel Sánchez-Ortega) to support all medical aspects within the organization, a **HR Coordinator** (Áurea Villar) and **IT Coordinator** (Bernat Sifre) to better support our organization and mission.

Further implementation of the restructured organigram will continue in 2020 to strengthen the efficiency and mission goals of the EBMT.

Acknowledgments

Acknowledgments to the EBMT Scientific Council and President of the Nurses Group

Mohamad Mohty
SCIENTIFIC COUNCIL REPRESENTATIVE WITH THE EDUCATION PORTFOLIO
CHAIRPERSON ALWP

Regis Peffault de Latour
SCIENTIFIC COUNCIL CO-CHAIR WITH THE RESEARCH AND SCIENCES PORTFOLIO
CHAIRPERSON SAAWP

Raffaella Greco
CHAIRPERSON ADWP DEFINITIONS COMMITTEE REPRESENTATIVE

Ibrahim Yakoub-Agha
CHAIRPERSON CMWP

Christian Chabannon
SCIENTIFIC COUNCIL REPRESENTATIVE WITH THE REGISTRY PORTFOLIO CHAIRPERSON CTIWP

Arjan Lankester
CHAIRPERSON IEWP

Rafael de la Camara
CHAIRPERSON IDWP

Grzegorz W. Basak
SCIENTIFIC COUNCIL REPRESENTATIVE WITH PORTFOLIO EDUCATION
CHAIRPERSON TCWP

Bertram Glass
CHAIRPERSON LWP

Selim Corbacioglu
SCIENTIFIC COUNCIL CHAIR WITH THE RESEARCH AND SCIENCES PORTFOLIO
CHAIRPERSON PDWP

Acknowledgments to the EBMT Scientific Council and President of the Nurses Group

Mohamad Mohty

SCIENTIFIC COUNCIL REPRESENTATIVE WITH THE
EDUCATION PORTFOLIO
CHAIRPERSON ALWP

Regis Peffault de Latour

SCIENTIFIC COUNCIL CO-CHAIR WITH THE RESEARCH
AND SCIENCES PORTFOLIO
CHAIRPERSON SAAWP

Raffaella Greco

CHAIRPERSON ADWP

Ibrahim Yakoub-Agha

CHAIRPERSON CMWP

Christian Chabannon

SCIENTIFIC COUNCIL REPRESENTATIVE WITH THE
REGISTRY PORTFOLIO
CHAIRPERSON CTIWP

Arjan Lankester

CHAIRPERSON IEWP

Rafael de la Camara

CHAIRPERSON IDWP

Grzegorz W. Basak

SCIENTIFIC COUNCIL REPRESENTATIVE WITH PORTFOLIO
EDUCATION
CHAIRPERSON TCWP

Bertram Glass

CHAIRPERSON LWP

Selim Corbacioglu

SCIENTIFIC COUNCIL CHAIR WITH THE RESEARCH AND
SCIENCES PORTFOLIO
CHAIRPERSON PDWP

John Murray

Nurses Group President

Acknowledgments to the Executive Committee



John Snwoden
Secretary



Harry Dolstra
Treasurer



Andreu Gusi
Executive Director

Acknowledgments to the EBMT Staff Members



Acknowledgments to Rafael Duarte, EBMT 2020 Congress President and Anna Sureda, Scientific Chair






Secretary's Report Year 2019

John Snowden, EBMT Secretary

Membership Overview

Global Figures



CENTRES Membership Overview

Global Figures

	GAM 2020	GAM 2019
<i>Number of EBMT CENTRES</i>	574	583
<i>Of which PROVISIONAL centres</i>	15	15
<i>Of which have been REACTIVATED</i>	3	6
<i>Of which FULL centres reporting</i>	505	518
<i>Of which ASSOCIATE centres</i>	54	53

Source: Promise January 2020

CENTRES Membership Overview

Per country

Position	Country	Number of centres GAM 2020	Number of centres GAM 2019
1	Germany	86	88
2	Italy	80	84
3	UK	52	54
4	France	51	51
5	Spain	46	46
6	Turkey	40	42
7	Poland	20	20
8	Belgium	15	16
9	The Netherlands	13	15
10	Switzerland	12	13

The **575** EBMT centres are located in **71** countries

The **top 10** split of Centres represents **415** Centres (72% of total)

Source: Promise January 2020

CENTRES

New EBMT
members

Membership

The following 15 Provisional Centre Members await your approval

CIC	Institution	City	Country
343	Kepler Universitätsklinikum Linz	Linz	Austria
475	Yeni Yüzyıl Üniversitesi Gaziosmanpaşa Hospital	İstanbul	Turkey
476	Hospital Virgen de la Victoria	Malaga	Spain
477	Middle East University Hospital	Bsalm	Lebanon
478	Mazumdar Shaw Cancer Center Narayana Health	Bangalore	India
481	Soroka University Medical Center	Beer Sheva	Israel
482	Apollo CBCC Cancer Care	Gandhinagar	India
483	Wits Donald Gordon Medical Centre	Johannesburg	South Africa
484	Hospital Sao Rafael	Salvador de Bahia	Brazil
607	Cardarelli Hospital	Napoli	Italy
887	Hospital Universitario Quiron Salud	Madrid	Spain
888	Odense University Hospital	Odense	Denmark
889	Dr Karen Gunther and Associates Inc	Johannesburg	South Africa
890	The South African National Blood Services SANBS	Johannesburg	South Africa
998	Instituto de Cancerologia S.A	Medellin	Colombia

CENTRES Membership Overview

Centers Membership Status Changes

The following number of member centers have had their membership status changed due to data reporting:

- **Full to Associate: 5**

5 Centers have stopped reporting and have been moved from Full members to ASSOCIATE

- **Associate to Full: 1**

1 Centre has resumed reporting and has been moved from Associate to FULL

INDIVIDUAL Membership

Overview

Global Figures

	GAM 2020	GAM 2019
Number of INDIVIDUAL members	144	125
<i>Of which PROVISIONAL centres</i>	38	13
<i>Physicians</i>	100	82
<i>Nurses</i>	38	40
<i>Other</i>	3	2
<i>Patient Representative</i>	2	1
Honorary members	30	34

Source: Promise January 2020

INDIVIDUAL Membership

Overview

New EBMT members

The following 38 Provisional Individual Members await your approval

CIC	Name	Role	Country
10126	Ali Irfan Emre Tekgunduz	Physician	Turkey
10192	Deepti Suri	Physician	India
10193	Anne Rajatammi	Nurse	Finland
10836	Bhagirathbhai Dholaria	Physician	USA
10837	Alina Volkova	Physician	Ukraine
10838	Su Han Lum	Physician	UK
10839	Sheetal Thakur	Nurse	India
10840	Alim Janhavi	Nurse	India
10841	Suman Kubal	Nurse	India
10842	Mobil Akhmedov	Physician	Russia
10843	Imran Ahmad	Physician	Canada
10844	Ali Sobh	Physician	Egypt
10845	Anil Aribandi	Physician	India

CIC	Name	Role	Country
10846	Isabel Salcedo	Nurse	Spain
10847	Muneer Hyder Abidi	Physician	USA
10848	Usama Gergis	Physician	USA
10849	Sameer Tulpule	Physician	India
10850	Shahed Ahmad Chowdhury	Physician	Bangladesh
10851	Rafiquzzaman Khan	Physician	Bangladesh
10852	Tuula Lappalainen	Nurse	Finland
10853	Soulaiman Elias	Physician	Syria
10854	Janet Baker	Nurse	UK
10855	Adrin Dadkhah	Student	Germany
10856	Sarah Ware	Nurse	UK
10859	Dimitrios Protogiros	Nurse	Greece
10860	Gonzalo Ariel Ferini	Physician	Argentina
10861	Gerhard Zugmaier	Physician	Germany
10862	Wasantha Rathnayake	Physician	Sri Lanka
10863	Syed Ziauddin Zaidi	Physician	Saudi Arabia
10864	Jose Ulysses Amigo Filho	Physician	Brazil
10865	Dalia Abd Elaziz	Physician	Egypt

CIC	Name	Role	Country
10866	Carin Smand	Other	Netherlands
10867	Marcia Garnica	Physician	Brazil
10868	Bregje Verhoeven	Patient Advocate	Netherlands
10870	Fernando Duarte	Physician	Brazil
10871	Samar Elbahy	Physician	Egypt
10872	Ahmad Darwish Mohamad Ibrahim	Physician	Egypt
10873	Ali Chamseddine	Physician	France

2020 Election Results

From the 9th to the 29th of April, the 505 Principal Investigators of EBMT centre members were invited to vote to show their support for the nominated and approved candidates in addition to approving the 2019 annual reports.

EBMT EXECUTIVE COMMITTEE MEMBER

Secretary
candidate

Total eligible voters: 505	Votes	Percentage
John Snowden (Sheffield, UK)	143	100%
<i>Abstain</i>	11	

505 voters – 156 votes

EBMT WORKING PARTY CHAIRS

ADWP Chair
candidates

Total eligible voters: 505	Votes	Percentage
Tobias Alexander (Berlin, Germany)	57	39%
Raffaella Greco (Milan, Italy)	91	61%
<i>Abstain</i>	8	

505 voters – 156 votes

EBMT WORKING PARTY CHAIRS

IDWP Chair

candidate

Total eligible voters: 505	Votes	Percentage
Rafael de la Camara (Madrid, Spain)	144	100%
<i>Abstain</i>	<i>7</i>	

505 voters – 156 votes

EBMT WORKING PARTY CHAIRS

LWP Chair

candidate

Total eligible voters: 505	Votes	Percentage
Bertram Glass (Berlin, Germany)	139	100%
<i>Abstain</i>	<i>15</i>	

505 voters – 156 votes

EBMT ANNUAL REPORTS

In addition to voting online for the nominated candidates, Pls were also asked to approve the annual reports (President's Report, Secretary's Report and the Treasurer's) in advance of the annual general assembly meeting.

President's Report - approval of EBMT's activities in 2019

Total eligible voters: 505	Votes	Percentage
Yes (approved)	145	99%
No (not approved)	1	1%
<i>Abstain</i>	<i>11</i>	

505 voters – 157 votes

Treasurer's Report - approval of the 2019 budget

Total eligible voters: 505	Votes	Percentage
Yes (approved)	144	100%
No (not approved)	0	0%
<i>Abstain</i>	15	

505 voters – 159 votes

Secretary's Report - approval of 2019-2020 membership (provisional to full)

Total eligible voters: 505	Votes	Percentage
Yes (approved)	146	99%
No (not approved)	1	1%
<i>Abstain</i>	12	

We would like to take the opportunity to thank the outgoing Board Members for their support to the EBMT scientific council during their mandate from 2016 to 2020:

- Rafael Duarte – EBMT Secretary
- John Snowden – ADWP Chair
- Jan Styczynski – IDWP Chair
- Silvia Montoto – LWP Chair



Treasurer's Annual Financial Report for 2019

Harry Dolstra, EBMT
Treasurer

<https://www.charitywatch.org/charitywatch-criteria-methodology>

Program %	Cost to Raise \$100	Efficiency Rating
90-100%	\$0 - 4	A+
80 - 89%	\$5 - 11	A
75 - 79%	\$12 - 15	A-
72 - 74%	\$16 - 19	B+
68 - 71%	\$20 - 26	B
65 - 67%	\$27 - 30	B-
61 - 64%	\$31 - 33	C+
56 - 60%	\$34 - 37	C
50 - 55%	\$38 - 40	C-
36 - 49%	\$41 - 59	D
0 - 35%	\$60 - 100	F

2019 + 2018 + 2017

A range = Excellent

B range = Good

C range = Satisfactory / Average

D = Unsatisfactory / Poor

F = Failing

Cancer Research Institute A
City of Hope & Affiliates A-
Leukemia & Lymphoma Soc. A-
American Red Cross B+

Final Conclusions

The continued positive financial development of the organization has allowed EBMT to further building on strategic goals and improve its structure.

Currents highlights: in-housing educational events, e-learning, registry upgrade, cellular therapy registry, benchmarking system, CART PASS.

A total of € 500K will be earmarked in line with the board decisions for structural innovation (€ 300K) and registry implementation (€ 200K).

A total of € 197K will be earmarked for running projects.

The residual budget of € 3,461K will be returned to our reserves and used to further secure our key staff positions and main strategic projects in case of any unforeseen financial serious adverse event.

Additionally, € 1,067K will be used in 2020 to strategically invest in the goals mentioned above.

Covid-19


Due to the current issues with regard to the Covid-19 virus the EBMT has announced to move some of its events. The date of the annual congress 2020 is moved to 29 August – 1 September 2020. This will have a negative impact on the forecasted net result of 2020. Until the exact financial impact is known, measures have been to reduce the pace of implementation of our strategic plans.

Current cost estimate 1 M Euro loss


EBMT has closed for a sixth consecutive year with a positive result

- During last years the changed financial model allowed creation of a continuous reserve of income for strategic projects.
- This permitted a 14% increase in staff positions but also augmented financial obligations.


(A) NUMBER OF FTE EMPLOYEES



(B) TOTAL SALARY COSTS



(C) GROSS INCOME



- At the very same time we increase our reserves from € 2,267K in 2014 to € 8,720K in 2019 to cover salary costs incase of any unexpected event.

Spending our financial resources on our missions

Our increasing annual income has been used to further work on our mission and improve the organizational structure of EBMT in order to strengthen our growing organization for achieving our mission goals.

The budget needed for management (i.e. board and executive office expenses) decreased to 8,8% which is resulting in allocating 91,2% to our scientific studies, Registry, accreditation and education including the Annual Meeting, E-learning and Educational events (Figure 2 Financial highlights 2019).

Therefore, EBMT remains a very efficient organization when assessed by international rankings (A+ in line with CharityWatch)



Implementing the well-balanced strategic financial roadmap

In 2019, the main challenge was to implement and optimize EBMT's organization through a well-balance financial roadmap for the future in order to be able to cover all financial challenges in line with our ambitions but also further strengthen a strong backbone.

The EBMT Board decided to partially release allocated reserves in 2020 (1.067 k€) to support our roadmap and EBMT organization for the next few years which covers the following 7 strategic topics:

1) IMPLEMENTING MACRO REGISTRY

In 2019 we continued to work on the migration of the Registry into MACRO. This project will be finalized in 2020 and has the highest financial priority. Reserves have been earmarked to cover all expected costs. In addition, reserves are being used and held for any unexpected expenses.

2) RESTRUCTURING THE ORGANIGRAM

In 2019 we restructured the managerial infrastructure of the EBMT and organized it in six departments, which are the Science, Registry, Educational, JACIE, Support and Business departments. Each department is led by a department head that together with the Executive Director form the EBMT management team.

Furthermore, we recruited a Medical Officer to support all medical aspects within the organization, and an HR Coordinator and IT Coordinator to better support our organization and mission. Further implementation of the restructured organigram will continue in 2020 to strengthen the efficiency and mission goals of the EBMT.

3) *SETTING UP SUCCESSFUL BUSINESS UNIT*

In 2019 we continued with setting up the business unit in order to increase and streamline the process of setting up retrospective and prospective studies in collaboration with pharma, institutions and non-profit organizations.

The funded studies are a growing segment of the activities of EBMT, and my compliments go to the business, operational and finance teams in the Leiden office to streamline the contracting of the scientific studies.

4) *STARTING THE CAR T PASS STUDIES*

In receiving the qualification opinion from EMA on the cellular therapy module of the EBMT Registry, the Board decided to strengthen manpower to support this initiative, which will collect post-market evidence for safety and efficacy of different commercial CART products. The first contract with Novartis has been signed and more companies are likely to follow. The finance involved in these contracts allow more manpower to execute these PASS studies and increase the Registry data and quality.

In addition, this registry tool will also be helpful for all researchers who are executing clinical studies with immune effector cells in order to gather more comprehensive data sets.

5) LAUNCHING THE BENCHMARKING PROJECT

In order to finance the “benchmarking project”, which will allow centres to know their own clinical transplantation outcomes compared to the rest of Europe (Snowden et al. BMT 2019), we have increased the JACIE fees.

Furthermore, for the first time we have an internal Medical Officer within the EBMT organization to support benchmarking reporting. In 2020 we will give back valuable information to each reporting centre about the quality of their daily clinical care.

6) *CONSOLIDATING THE EDUCATION & EVENTS UNIT*

The in-housing process of the Annual Meeting and educational events by the Barcelona office continues to be a huge success in order to increase the EBMT's positioning and visibility and to improve financial control.

7) IMPLEMENTING E-LEARNING TOOLS

We further invested in developing a sophisticated e-learning platform, which will allow the community to further educate themselves with online training.



AUDITING PROCESS

At the time of preparation this presentation (18 March 2020), the audit process had not yet been completed.

No information from the auditors has reached us that indicates we won't obtain an "unqualified opinion".

It will be the fifth consecutive time EBMT obtains an unqualified opinion. This demonstrates that the EBMT is maintaining its high standard of modern management, improving its financial stability and provides assurance that money is spent and allocated according to our mission.

At the end of the audit process EBMT will receive a **Auditor's Management Letter**. The outcome of this will be presented in the Board meeting after obtaining the letter.

Financial options for future strategic goals in and beyond 2019

Further development of the registry

Implementing benchmarking

Implementing the cellular therapy project and PASS

studies Investing in IT and human resources

Developing e-Learning content

Risk management:

EBMT's liquidity

- **Current ratio:** liquidity of an organization
 - This indicator says something about the financial position of the organization. It shows if current liabilities can be covered from the current assets. A ratio of 1,2 – 1,5 is considered as healthy.
 - **Current ratio** = Current assets / current liabilities (disadvantage snap shot and can substantially change per time point through the year)

Liquidity

$$\text{Current ratio} = \frac{16.882.000}{7.044.000} = 2,4$$

- **Cash runway:** How long can the organization run without income
 - **Cash runway ratio** = Current assets / current + future liabilities
 - **Burn:** approximately **1 Mio Euro a month**

Liquidity

$$\text{Runway ratio } 12 \times \frac{16.882.000}{11.983.000} = 16,9$$



47th Annual Meeting of the European Society for Blood and Marrow Transplantation

14-17 March 2021
Madrid, Spain